Hepatitis C virus and inflammatory bowel disease

Digestive Diseases and Sciences

Volumn 54, Issue 6, 2009, Pages 1171-1177

  Horn, Todd L ^a   Reynolds, Joel ^a   De Villiers, Willem ^a   Peña, Luis R ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Crohn's disease; Hepatitis C virus; Inflammatory bowel disease; Infliximab; Interferon; Therapy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERFERON; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; RIBAVIRIN; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ANTIVIRAL THERAPY; CLINICAL TRIAL; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RATE; INFECTION RISK; LIVER DYSFUNCTION; LIVER TOXICITY; MONOTHERAPY; PATIENT SAFETY; PRIORITY JOURNAL; REINFECTION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS;

EID: 67349251600     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0489-2     Document Type: Review

References (42)

1. F Longo X Hebuterne A Tran 2000 Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors Gastroenterol Clin Biol 24 1 77 81 (Pubitemid 30117236)
2. JP Bronowicki H Barraud L Peyrin-Biroulet 2005 Epidemiology and natural history of hepatitis C Rev Prat 55 6 607 614 (Pubitemid 40543949)
3. L Biancone M Pavia G Del Vecchio Blanco 2001 Hepatitis B and C virus infection in Crohn's disease Inflamm Bowel Dis 7 4 287 294 (Pubitemid 33062093)
4. A Khalil D Lucidarme P Desurmont 2005 Crohn's disease associated with interferon and ribavirin treatment for chronic hepatitis C Gastroenterol Clin Biol 29 2 193 196 (Pubitemid 40385081)
5. F Villa MG Rumi C Signorelli 2005 Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases Eur J Gastroenterol Hepatol 17 11 1243 1245 (Pubitemid 41527444)
6. C Mavrogiannis IS Papanikolaou IS Elefsiniotis 2001 Ulcerative colitis associated with interferon treatment for chronic hepatitis C J Hepatol 34 6 964 965 (Pubitemid 32595203)
7. R Sprenger M Sagmeister F Offner 2003 Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis Gut 52 12 1728 1733
8. T Niki K Nishida Y Honsako 2001 A case of ulcerative colitis along with characteristic features on computed tomography (CT), developed by the treatment with interferon for chronic hepatitis C Nippon Shokakibyo Gakkai Zasshi 98 4 399 404 (Pubitemid 33740622)
9. T Watanabe M Inoue K Harada 2006 A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin Gut 55 11 1682 1683 (Pubitemid 44629245)
10. A Mitoro M Yoshikawa K Yamamoto 1993 Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C Intern Med 32 4 327 331 (Pubitemid 23282340)
11. Y Yamamoto N Sakatani S Yano 1995 Interferon-induced IBD-like acute colitis-two cases of patients with chronic active hepatitis Nippon Shokakibyo Gakkai Zasshi 92 9 1293 1296
12. M Cottone A Magliocco G Trallori 1995 Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis Ital J Gastroenterol 27 1 3 4
13. S Bargiggia D Thorburn A Anderloni 2005 Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study Aliment Pharmacol Ther 22 3 209 215 (Pubitemid 41153063)
14. H Tilg H Vogelsang O Ludwiczek 2003 A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis Gut 52 12 1728 1733 (Pubitemid 37510393)
15. M Esteve C Saro F Gonzalex-Huix 2004 Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis Gut 53 1363 1365 (Pubitemid 39120128)
16. Y Ueno S Tanaka M Shimamoto 2005 Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B Dig Dis Sci 50 163 166 (Pubitemid 40379157)
17. M Garcia-Sanchez F Gomez-Camacho A Poyato-Gonzalez 2004 Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection Inflamm Bowel Dis 10 701 702 (Pubitemid 39294531)
18. D Wendling B Auge D Bettinger 2005 Reactivation of a latent precore mutant hepatitis B virus-related chronic hepatitis during infliximab treatment for severe spondyloarthropathy Ann Rheum Dis 64 788 789 (Pubitemid 40559316)
19. P Ostuni C Botsios L Punzi 2003 Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low-dose methotrexate Ann Rheum Dis 62 686 687 (Pubitemid 36760576)
20. M Michel C Duvoux C Hezode 2003 Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult-onset Still's disease J Rheum 30 1624 1625 (Pubitemid 36835467)
21. JR Peterson FC Hsu PA Simkin 2003 Effect of tumor necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection Ann Rheum Dis 62 1078 1082 (Pubitemid 37323572)
22. O Oniankitan C Duvoux D Challine 2004 Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C J Rheum 31 107 109 (Pubitemid 38067531)
23. FA Parke JD Reveille 2004 Anti-tumor necrosis factor agents for RA in the setting of chronic hepatitis C infection Arthritis Rheum 51 800 804 (Pubitemid 39372039)
24. CH Roux O Brocq V Breuil 2006 Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis Rheumatology 45 10 1294 1297 (Pubitemid 44542073)
25. S Aslanidis T Vassiliadis A Pyrpasopoulou 2007 Inhibition of TNF-alpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases Clin Rheumatol 26 2 261 264 (Pubitemid 46020258)
26. G Pitarch JL Sanchez-Carazo L Mahiques 2007 Treatment of psoriasis with adalimumab Clin Exp Dermatol 32 1 18 22 (Pubitemid 46006359)
27. S Campbell S Ghosh 2001 Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection Eur J Gastroenterol Hepatol 13 191 192 (Pubitemid 32158214)
28. MH Holtmann PR Galle MF Neurath 2003 Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF Am J Gastroenterol 98 504 505 (Pubitemid 36232412)
29. NN Zein Etanercept Study Group 2005 Etanercept as an adjuvant to interferon and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study J Hepatol 42 3 315 322 (Pubitemid 40254244)
30. DM Nathan PW Angus PR Gibson 2006 Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach J Gastroenterol Hepatol 21 9 1366 1371 (Pubitemid 44154702)
31. JR Stangl KL Carroll M Illichmann 2004 Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus Transplantation 77 4 562 567 (Pubitemid 38282813)
32. DN Samonakis CK Triantos 2005 Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation Liver Transpl 11 4 384 385 (Pubitemid 40533206)
33. A Zekry M Gleeson S Guney 2004 A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection Liver Transpl 10 1 52 57 (Pubitemid 38885893)
34. T Walter J Dumortier O Guillaud 2007 Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsiesin a single center Liver Transpl 13 2 294 301 (Pubitemid 46351657)
35. AM Contreras FJ Monteon MR Flores 2007 Drug-related hepatotoxicity in a renal transplant recipient with long-term survival and hepatitis C Ann Hepatol 6 1 70 73 (Pubitemid 46407494)
36. MY Mok WL Ng MF Yuen 2000 Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis Clin Exp Rheumatol 18 3 363 368 (Pubitemid 30409106)
37. A Kujawska M Clements CM Wise 2003 Hepatitis C and methotrexate Arthritis Rheum 49 6 843 845 (Pubitemid 37523638)
38. RJ Firpi H Zhu G Morelli 2006 Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation Liver Transpl 12 1 51 57
39. LL Schiavon RJ Carvalho-Filho JL Narciso-Schiavon 2008 Impact of cyclosporine-based immunosuppressive therapy on liver histology of hepatitis C virus-infected renal transplant patients Hepatology 48 1 348 349
40. RH Wiesner JS Shorr BJ Steffen 2005 Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C Liver Transpl 11 7 750 759 (Pubitemid 40975576)
41. F Sánchez-Bueno ML Ortiz J Bermejo 2006 Prognostic factors for hepatitis C recurrence in patients undergoing orthotopic liver transplantation Transpl Immunol 17 1 47 50
42. T Kato JJ Gaynor H Yoshida 2007 Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at 1 year Transplantation 84 7 829 835